Magnesium Sulphate Ethypharm (Magnesium Sulfate Heptahydrate)

Magnesium sulfate acts as a calcium antagonist, blocking calcium entry into cells, stabilising membranes, reducing neuromuscular excitability, and causing vasodilation. These actions help control seizures, correct electrolyte imbalances, suppress abnormal cardiac rhythms, and relax bronchial smooth muscle.

The specific dose and infusion rate are determined by the prescribing clinician based on the indication, patient weight, renal function and clinical response. Healthcare professionals should follow local guidelines and monitor serum magnesium levels during therapy.

Magnesium sulfate is commonly used in pregnancy for eclampsia management and is considered relatively safe when administered under medical supervision. Limited data exist for breastfeeding, but small amounts are excreted in milk; clinicians should weigh benefits against potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Compared with other anticonvulsant agents, magnesium sulfate offers a dual benefit of seizure control and electrolyte replacement, making it uniquely suited for eclampsia and certain arrhythmias. Unlike benzodiazepines, it does not cause respiratory depression at therapeutic levels, but it requires careful monitoring of serum magnesium and renal function.

Magnesium Sulphate Ethypharm injection solution should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the vial. If temperature excursions occur, discard the product according to local regulations.

The product is supplied as a sterile injection solution for intramuscular or intravenous administration. Intravenous infusion is typically given via a controlled infusion pump, while intramuscular injection is performed using standard aseptic technique. Administration routes and rates are dictated by the clinical indication and physician orders.

The most serious risks include hypermagnesemia leading to respiratory depression, severe hypotension, cardiac arrhythmias or arrest, and anaphylactic reactions. Prompt recognition of symptoms such as loss of deep tendon reflexes, respiratory compromise or profound hypotension is essential, and treatment should be initiated immediately.

Patients with severe renal impairment, known hypersensitivity to magnesium sulfate, myasthenia gravis, or those receiving potent neuromuscular blocking agents should avoid this medication unless closely monitored. Contraindications also include uncontrolled heart block or severe hypotension without appropriate resuscitative measures.